Abstract: A pharmaceutical composition is described which includes diclofenac as an active ingredient. The pharmaceutical composition further includes a (meth)acrylic polymer which has a specific solubility and/or a particular functional group in one polymer component.

Abstract: A pharmaceutical composition is described which includes diclofenac as an active ingredient. The pharmaceutical composition further includes a (meth)acrylic polymer which has a specific solubility and/or a particular functional group in one polymer component.

Abstract: Taste-masked Ibuprofen granules and a process for preparation thereof, as well as an oral dosage form including such taste-masked Ibuprofen granules and the use of said granules in an oral dosage form.

Abstract: An orally disintegrating tablet comprising acetylsalicylic acid, acetaminophen and caffeine and one or more pharmaceutically acceptable excipients.

Abstract: A tablet, containing an inner phase, comprising a) a first type of pellets (I) which contain a first active ingredient and which have a coating and/or release the active ingredient in a modified manner, or b) a first type of coated first active ingredient (I), mixed with c) spherical particles (II), and an outer phase containing one or more excipients present in non-granulated form before tableting, selected from disintegrants, lubricants, flow regulators, fillers and binders, wherein the weight of the outer phase makes up not more than 25 percent of the total weight of the tablet.

Abstract: The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component (a) of 60% or less after 10 minutes and 95% or less after 20 minutes, and a dissolution profile of component (b) of 25% or more after 30 minutes, and 45% or more after 60 minutes at pH 4.5, said pharmaceutical oral fixed dose combination being bioequivalent to a free dose combination of Aliskiren and Valsartan.

Abstract: The invention relates to a method for improving the fluidity and/or the spreadability of the native lung surfactant in a human or animal in need of such treatment, wherein the human or animal is administered with a fluorocarbon composition. The invention further relates to therapeutic compositions comprising a fluorocarbon, optionally in combination with a phospholipid, and their use as lung surfactant supplements.